These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9827211)

  • 1. [Iron homeostasis and Parkinson's disease].
    Faucheux BA; Hirsch EC
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():23-30. PubMed ID: 9827211
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relationship between iron metabolism in central nervous system and Parkinson's disease].
    Wang J; Jiang H; Xie JX
    Sheng Li Ke Xue Jin Zhan; 2003 Jan; 34(1):67-70. PubMed ID: 12778816
    [No Abstract]   [Full Text] [Related]  

  • 4. The current state of free radicals in Parkinson's disease. Nigral iron as a trigger of oxidative stress.
    Friedman A; Galazka-Friedman J
    Adv Neurol; 2001; 86():137-42. PubMed ID: 11553971
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Eshel G; Finberg JP; Riederer P
    Adv Neurol; 1993; 60():259-66. PubMed ID: 8380520
    [No Abstract]   [Full Text] [Related]  

  • 8. Transferrin receptor regulation in Parkinson's disease and MPTP-treated mice.
    Mash DC; Sanchez-Ramos J; Weiner WJ
    Adv Neurol; 1993; 60():133-9. PubMed ID: 8420130
    [No Abstract]   [Full Text] [Related]  

  • 9. [Oxidative stress and the brain].
    Tanaka M
    Nihon Ronen Igakkai Zasshi; 1997 Sep; 34(9):706-10. PubMed ID: 9430979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
    Yantiri F; Andersen JK
    IUBMB Life; 1999 Aug; 48(2):139-41. PubMed ID: 10794588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular mechanisms of dopamine toxicity.
    Barzilai A; Daily D; Zilkha-Falb R; Ziv I; Offen D; Melamed E; Shirvan A
    Adv Neurol; 2003; 91():73-82. PubMed ID: 12442665
    [No Abstract]   [Full Text] [Related]  

  • 13. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
    Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
    Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
    Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
    Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron dysregulation and Parkinson's disease.
    Andersen JK
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S47-52. PubMed ID: 15665414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free radical and nitric oxide toxicity in Parkinson's disease.
    Przedborski S; Jackson-Lewis V; Vila M; Wu DC; Teismann P; Tieu K; Choi DK; Cohen O
    Adv Neurol; 2003; 91():83-94. PubMed ID: 12442666
    [No Abstract]   [Full Text] [Related]  

  • 17. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 18. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
    Saavedra A; Baltazar G; Santos P; Carvalho CM; Duarte EP
    Neurobiol Dis; 2006 Sep; 23(3):533-42. PubMed ID: 16766196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.